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The Burden of MNS Disorders
Mental, neurological, and substance use
disorders and related disabilities (MNS
disorders) are leading contributors to the
burden of disease globally. (The term MNS
is a relatively new acronym coined by the
World Health Organization [WHO] to
refer to the complete range of disorders of
the brain and the mind for its mental health
Gap Action Programme [mhGAP].) Uni-
polar depressive disorders, alcohol use
disorders, and self-inflicted injuries rank
within the top 20 leading causes of burden
of disease (as measured by disability adjust-
ed life years [DALYs]) across all age groups
and neuropsychiatric disorders, collectively,
account for 22% of DALYs for women aged
15–59 years [1]. Even in the least developed
regions of the world where infectious and
parasitic diseases are prominent, MNS
disorders are a major source of DALYs lost
[1]. Over the next 20 years, it is estimated
that neuropsychiatric disorders alone will
account for the loss of an additional
US$16.1 trillion with ‘‘dramatic impacts
on productivity and quality of life’’ [2].
Suicide claims the lives of at least 1 million
people annually [3] with over 85% of
suicides occurring in low- and middle-
income countries (LMICs). Nearly 4% of
all deaths globally are attributable to alcohol
[4]. While many MNS disorders begin in
childhood and adolescence (when an indi-
vidual is being educated, establishing effec-
tive social relationships, and preparing for
work), the burden associated with dementia
and stroke is expected to accelerate with
increasing life expectancies around the
world. Currently, it is estimated that about
25 million people have dementia; this
number is expected too reach over 80
million by 2040, with nearly three-quarters
of affected people living in LMICs [5].
MNS disorders are associated with low
rates of treatment, poor treatment adher-
ence, and increases in risky behaviors, thus
influencing the risk of and outcomes in
other noncommunicable (NCD) and com-
municable diseases. This association is bi-
directional. For example, depressive disor-
ders markedly increase the risk for NCDs
such as diabetes, coronary artery disease,
stroke, and dementia, and comorbidity of
depression and NCDs complicates treat-
ment and worsens prognosis for both [6].
Stigma and discrimination are frequently
experienced by people with MNS disor-
ders, showing similarities to the experience
of those with stigmatizing diseases like
HIV. Indeed, people with MNS disorders
suffer some of the worst abuses of human
rights in modern times [7]. Conflict,
displacement, poverty, gender-based vio-
lence, and other social determinants of ill
health increase the risk for MNS disorders
[8,9], and MNS disorders are, in turn,
associated with worsening of social and
economic circumstances, setting up a
vicious cycle of poverty and illness.
Addressing the Burden of MNS
Disorders
We have robust evidence on cost-
effective interventions that can be adapted
to meet the needs of people affected by a
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range of MNS disorders in different
contexts and cultures [10,11], and we
have confirmation that effective delivery
of such evidence-based interventions is
possible even in contexts with limited
resources [12–14]. We have evidence that
early detection and treatment can be
affordable and would have considerable
benefits for people, families, and commu-
nities. For example, more than 65% of
people with epilepsy can be successfully
treated with affordable drugs; in most
countries the cost of treatment can be as
low as US$5 per patient per year [15].
Research has shown that, in addition to
improving health states, the treatment of
MNS disorders also improves economic
well-being of the affected person [16], and
mounting evidence underscores the im-
portance of treatment of MNS disorders
for community- and state-level economic
and political development [17]. Neverthe-
less, an enormous treatment gap persists
throughout the world, particularly in the
least developed countries.
A number of challenges need to be
addressed in a global strategy for reducing
the burden of MNS disorders. These
challenges include inadequate resource
allocation, cultural and contextual influ-
ences on the manifestations of illness [18],
stigma and discrimination, shifting and
imprecise diagnostic systems, limited etio-
logical evidence, limited effectiveness of
interventions for the prevention and care of
some conditions, and the continued seques-
tration of mental health in siloed parellel
systems apart from general health services.
While there is a need for both specialty care
as well as for decentralization of services to
substantially expand access to treatment
and care, in many countries the treatment
and care for MNS disorders is predomi-
nantly in specialist hospitals in urban
centers [19], far from where most people
live, resulting in care for only a small
fraction of people with MNS disorders.
The time has come for recognition at
the highest levels of global development,
namely the UN General Assembly, of the
urgent need for a global strategy to address
the global burden of MNS disorders.
The Goals of the Proposed
UNGASS
The proposed UNGASS aims to posi-
tion MNS disorders as a global develop-
ment priority. The declaration presented
at the UNGASS should call for govern-
ments, multilateral agencies, and donors to
mobilize resources to implement actions to
address the burden of MNS disorders.
Three broad areas of action need urgent
investment.
The first is to enhance access to
evidence-based packages of care, for
example, by widely implementing the
WHO mhGAP guidelines [20] for the
treatment of MNS disorders. The delivery
of these interventions will need task-
shifting approaches and integration of
mental health care within primary health
care systems and in other sectors, such as
education and social welfare. We will need
to strengthen health systems and ensure
equitable access for marginalized popula-
tions such as persons displaced by conflict
and those who are socially disadvantaged.
Second, the human rights commitment
enshrined in the Convention on the Rights
of Persons with Disabilities [21] should be
realized to ensure that people with MNS
disorders live a life with dignity. There
should be no place in our world for placing
people with MNS disorders in chains, or
locking them away from their communi-
ties. Prisons should never be the de facto
care settings for people with MNS disor-
ders. The capacity of people with MNS
disorders to advocate for themselves must
be strengthened and supported.
Third, actions must be taken to expand
our knowledge about MNS disorders.
Even as advances in genetics and neuro-
science are improving our understanding
of MNS disorders, there have been no
major innovations in the prevention or
treatment for any MNS disorder in the
past two decades. A specific fund is
needed, perhaps modeled along the lines
of the Drugs for Neglected Diseases
Initiative, to fast-track discovery of new
pharmacological, psychological, and social
treatments and preventive interventions.
The fact that MNS disorders affect people
in all countries should offer considerable
incentive for investments by both public
and private sectors in this initiative.
Securing the commitment of a majority
of governments for a UNGASS will
require a concerted effort from the diverse
group of stakeholders concerned with
MNS disorders. Above all, persons affect-
ed by MNS disorders and their families
must be empowered to play a leading role
in advocating for their well-being and
rights. The Movement for Global Mental
Health (http://www.globalmentalhealth.
org/) and World Federation for Mental
Health (http://www.wfmh.org/) will work
together with the WHO and other multi-
lateral and civil society agencies to rally
support. Recently, the Board of the World
Federation for Mental Health (WFMH)
formally adopted a position to prioritize
the ‘‘grand challenge’’ for global mental
health related to transforming health
system and policy responses [22]. Building
on its recent efforts to advocate for mental
health in the global health agenda on
NCDs—such as the presentation of posi-
tion statements at the World Health
Assembly meeting and the WHO meeting
for health ministers in Moscow—WFMH
has launched its ‘‘Great Push for Mental
Health’’ program. This program includes
the development of a ‘‘People’s Charter
for Mental Health’’ that intends to trans-
late stakeholder identified priority needs
into practical actionable steps for country
implementation. This charter will be
developed in consultation with the orga-
nizations from 96 countries who have
signed up to the ‘‘Great Push’’ initiative so
far, representing over one million people
including consumers, family members,
advocates, researchers, professional orga-
nizations, and policy makers. Together,
this grand coalition of local, national, and
global actors will converge their energies
towards the implementation of a UNGASS
to achieve the ultimate goal of reducing the
global burden of MNS disorders.
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Summary Points
N Mental, neurological, and substance use (MNS) disorders are leading causes of
the global burden of disease and profoundly impact the social and economic
well-being of individuals and communities.
N The majority of people affected by MNS disorders globally do not have access
to evidence-based interventions and many experience discrimination and
abuses of their human rights.
N A United Nations General Assembly Special Session (UNGASS) is needed to
focus global attention on MNS disorders as a core development issue requiring
commitments to improve access to care, promote human rights, and
strengthen the evidence on effective prevention and treatment.
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